How Your Gut Microbiome Shapes Menopause Symptoms and Health Risks

Why this matters: Menopause affects roughly half the global population, typically between ages 45–55, and is associated with a cascade of symptoms from hot flushes to bone loss and cognitive decline. Emerging science now implicates the gut microbiome as a previously underappreciated player in how severely women experience these transitions—and how long they last.

What was studied: This narrative review synthesizes evidence from human cohorts, animal models, and intervention trials to map the interplay between gut microbial composition, sex hormone metabolism, and menopausal health outcomes. The authors specifically examine the 'estrobolome'—a collection of bacterial genes encoding enzymes like β-glucuronidases and sulphatases—that deconjugate estrogens excreted via bile, enabling their reabsorption into systemic circulation.

Key findings: Postmenopausal women show gut microbiota profiles that resemble age-matched men more than premenopausal women, with reduced Lachnospira, Roseburia, and Firmicutes, and elevated Bacteroidetes and Tolumonas. Roseburia depletion is linked to metabolic disease, while Tolumonas overrepresentation negatively correlates with bone mineral density. Women with menopausal syndrome (MPS) showed gut dysbiosis absent in healthy menopausal controls, with enriched metabolic pathways associated with cardiovascular disease. Gut permeability, measured via FABP2 in the SWAN cohort, increases during menopausal transition and correlates with systemic inflammation. The estrobolome's β-glucuronidase activity inversely associates with gut estrogen levels but positively with systemic estrogen richness.

Therapeutic implications: Probiotic interventions—especially Lactobacillus-based—and dietary prebiotics (particularly fibre) show promise in restoring microbial diversity, improving the Firmicutes:Bacteroidetes ratio, and reducing metabolic and inflammatory markers in menopausal women. These interventions may offer a complementary or adjunct strategy to hormone replacement therapy, particularly for women who cannot or prefer not to use HRT.

Caveats: The review highlights significant inconsistency across existing studies, most of which compare postmenopausal women to premenopausal women without adequately controlling for age. The gut-microbiota-brain axis in the context of menopause remains largely uninvestigated. Mechanistic data supporting specific probiotic formulations or dosing regimens are sparse, and large, well-controlled randomised trials are still needed before clinical recommendations can be made.